Innovations in Obesity Treatment

This chapter explores Zeeland Pharma's groundbreaking amylin-based treatment strategy in the obesity market, underscored by a pivotal partnership with Roche worth $1.65 billion. It emphasizes the competitive landscape, the necessity for innovative manufacturing capabilities, and the implications of partnering for developing effective therapies. Additionally, it highlights the unique advantages of Petrolintide for patient satisfaction and sustainable weight management, setting it apart from conventional GLP-1 medications.